KaydedilenlerDerginizi ekleyin

Dergiler / Acta Medica / 2018 / Cilt: 49 - Sayı: 3

Circulating cell free DNA and miRNA Amount in Congenital Hearing Loss

Özge ÇAĞLAR
Akın ÇAYIR
Begum CILGIN
F. Sefa DEREKÖY
Sayfa
19–23
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: The miRNA and freeDNA can be used early in the diagnosis of congenital hearing loss.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Our aim is to detect the amount of miRNA and free DNA in the peripheral blood of young people with congenital hearing loss and compare this with control group.
📊
Temel Bulgular & Veri:Materials and Methods: In our study, 16 patients who have congenital hearing loss and go to the private school for deaf children and 16 healthy individuals were select- ed in the same age group. 5 cc blood was taken from peripheral vessels of each individual.
💡
Sonuç & Katkı:Conclusion: The miRNA and freeDNA can be used early in the diagnosis of congenital hearing loss.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: Our aim is to detect the amount of miRNA and free DNA in the peripheral blood of young people with congenital hearing loss and compare this with control group. Materials and Methods: In our study, 16 patients who have congenital hearing loss and go to the private school for deaf children and 16 healthy individuals were select- ed in the same age group. 5 cc blood was taken from peripheral vessels of each individual. We compared the circulating cell-free DNA and miRNA amount with the results of the control group. Results: The ccfDNA amount of the patients with hearing loss was lower than the control group and It was statistically significant. On the contrary, we found the high- er amount of ccfmiRNA in plasma samples of the patients with hearing loss. The statistical analysis showed that ccfmiRNA amount in congenital loss is consistently sig- nificantly higher than the control group. Conclusion: The miRNA and freeDNA can be used early in the diagnosis of congenital hearing loss.

🔖

Bu Makaleye Atıf Yap

ÇAĞLAR, Ö., ÇAYIR, A., CILGIN, B., DEREKÖY, F. S. (2018). Circulating cell free DNA and miRNA Amount in Congenital Hearing Loss. Acta Medica, Cilt: 49 - Sayı: 3, 19–23. https://ajindex.com/articles/144213

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (8)

  1. Mielczarek M, Zakrzewska A, Olszewski J. GJB2 sequencing in deaf and profound sensorineural hearing loss children. Otolaryngol Pol 2016; 70 (3): 21-25.
  2. Kochhar A, Hildebrand MS, Smith RJ. Clinical aspects of hereditary hearing loss. Genet Med 2007; 9(7): 393- 408. Putcha GV, Bejjani BA, Bableoo S, et al. A multicenter study of the frequency and distribution of GJB2 and GJB6 mutations in a large North American cohort. Genet Med 2007; 9(7) 413- 426. Nance WE, Lim BG, Dodson KM. Importance of congenital cytomegalovirus infections as a cause for pre-lingual hearing loss. J Clin Virol 2006; 35(2): 221- 225. McClay JE, Booth TN, Parry DA, et al. Evaluation of pediatric sensorineural hearing loss with magnetic resonance imaging. Arch Otolaryngol Head Neck Surg 2008; 134(9): 945-952.
  3. Prezant TR, Agapian JV, Bohlman MC, et al. Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. Nat Genet 1993; 4(3): 289- 294. Kimani JW, Buchman Ca, Booker JK, et al. Sensorineural Hearing Loss in a Pediatric PopulationAssociation of Congenital Cytomegalovirus Infection With Intracranial Abnormalities. Arch Otolaryngol Head Neck Surg. 2010; 136(10): 999-1004.
  4. Leon SA, Shapiro B, Sklaroff DM, et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977; 37(3): 646–650. [ Kirk GD, Lesi OA, Mendy M, et al. 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocel- lular carcinoma, Oncogene 2005; 24(38): 5858–5867.
  5. Mulcahy HE, Lyautey J, Lederrey C, et al. A pro- spective study of K-ras mutations in the plasma of pancreatic cancer pa- tients, Clin. Cancer Res. 1998; 4(2): 271–275.
  6. Salbe C, Trevisiol C, Ferruzzi E, et al. Molecular detection of codon 12 K-RAS mutations in circulating DNA from serum of colorectal cancer patients, Int. J. Biol. Markers 2000; 15(4): 300–307.
  7. Utting M, Werner W, Dahse R, et al. Microsatellite analysis of free tumor DNA in urine, serum, and plasma of patients: a minimally invasive method for the detection of bladder cancer, Clin. Cancer Res. 2002; 8(1): 35–40.
  8. Galeazzi M, Morozzi G, Piccini M, et al. Dosage and character- ization of circulating DNA: present usage and possible applications in systemic autoimmune disorders. Autoimmun Rev 2003; 2(1): 50–5. Steinman CR. Circulating DNA in systemic lupus erythemato- sus: Isolation and characterization. J Clin Invest 1984; 73(3): 832–41. Steinman CR. Circulating DNA in polyarteritis nodosa and relat